Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-05-10
2011-05-10
Aeder, Sean E (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
Reexamination Certificate
active
07939268
ABSTRACT:
The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
REFERENCES:
patent: 2003/0073129 (2003-04-01), Baker et al.
patent: 2004/0058340 (2004-03-01), Dai et al.
patent: 2006/0257911 (2006-11-01), Burford et al.
patent: 1 126 028 (2001-08-01), None
patent: 1 375 518 (2004-02-01), None
patent: WO 90/05540 (1990-05-01), None
patent: WO 00/12708 (2000-03-01), None
patent: WO 00/78961 (2000-12-01), None
patent: WO 01/42288 (2001-06-01), None
patent: WO 01/53312 (2001-07-01), None
patent: WO 0153312 (2001-07-01), None
patent: WO 01/60860 (2001-08-01), None
patent: WO 01/62273 (2001-08-01), None
patent: WO 01/64882 (2001-09-01), None
patent: WO 01/66689 (2001-09-01), None
patent: WO 01/68848 (2001-09-01), None
patent: WO 02/059377 (2002-08-01), None
patent: WO 03/018621 (2003-03-01), None
patent: WO 03/042661 (2003-05-01), None
patent: WO 03/083074 (2003-10-01), None
patent: WO 2005/058028 (2005-06-01), None
Yerushalmi et al (Gene, 2001, vol. 265, pp. 55-60).
Caillou et al (Journal of Clinical Endocrinology and Metabolism, 2001, vol. 86, pp. 3351-3351).
Stedman's medical dictionary, 25th ed, 1990, p. 1652-1653.
Russo, V et al, 1995, Int J Cancer, 64: 216-221.
Kibel, AS et al, 2000, J urol, 164(1): 192-6.
Dong et al, 2000, Cancer Research, 60: 3880-3883.
Stanton, P et al, 1994, Br J Cancer, 70: 427-433.
Iehle, C et al, 1999, J Steroid Biochem Mol Biol, 68: 189-195.
Abbaszadegan, M R, et al, 1994, Cancer Res, 54: 4676-4679.
Sadek et al., “Osteopontin” Crit Rev Oral Biol Med., vol. 11, No. 3 pp. 279-303 (2000) XP001022167.
Thalmann et al., “Osteopontin: Possible Role in Prostate Cancer Progression”, Clin. Cancer Research vol. 5, pp. 2271-2277 (1999) XP002348201.
Weber et al., “The Metastasis Gene Osteopontin: A Candidate Target for Cancer Therapy” Biochimica et Biophysica Acta 1552 (2001) 61-85 XP004334757.
Banki, et al., “Cloning and expression of the human gene for transaldolase”, The Journal of Biological Chemistry, vol. 269, No. 4, pp. 2847-2851, (1994).
Bendayan, et al., “Possibilities of false immunocytochemical results generated by the use of monoclonal antibodies: The example of the anti-proinsulin antibody”, The Journal of Histochemistry and Cytochemistry, vol. 43, No. 9, pp. 881-886, (1995).
Banki et al, 1994, JBC, 269 (4): 2847-51.
Bendayan et al, 1995, J Histochem Cytochem, 43(9): 881-886).
Miller, 1995 (FASEB J., vol. 9, pp. 190-199).
Deonarain, 1998 (Expert Opin. Ther. Pat., vol. 8 pp. 53-69).
Verma, Sep. 1997 (Nature, vol. 389, pp. 239-242).
Crystal, 1995 (Science, vol. 270, p. 404-410).
U.S. Appl. No. 60/298,918 and MPSRCH search result, 2006, us-10-872-972.93.mpbm, pp. 1-5.
Sambrook et al., (Molecular Cloning, A Laboratory Manual, 2ndEdition, Cold Springs Harbor Press, Cold Spring Harbor, p. 16.3-16.4), 1989.
Breenbaum et al., (genome biology, 2003, vol. 4, issue 9, pp. 117.1-117.8).
Fu et al., 1996 (EMBO Jounrnal, vol. 15, pp. 4392-4401).
Tokota, J et al., 1988 (Oncogene, vol. 3, pp. 471-475).
Zimmer, 1991 (Cell Motility and the Cytoskeleton, vol. 20, pp. 325-337).
Hell et al., 1995 (Laboratory Investigation, vol. 73, pp. 492-496).
Guo et al., 2002 (Journal of Pharmacology and Experimental Therapeutics, vol. 300, pp. 206-212).
White et al., 2001 (Ann Rev Med., 52:125-145).
Boon, 1992 (Adv. Can. Res., 58:177-210).
Ezzell, 1995 (J. NIH Res., 7:46-49).
Spitler, 1995 (Cancer Biotherapy, 10:1-3).
Gura, 1997 (Science, 278:1041-1042).
Jain, 1994 (Sci. Am., 271:58-65).
Curti, 1993 (Crit. Rev. in Oncology/Hematology, 14:29-39).
Hartwell et al. (Science, 1997, 278:1064-1068).
TAT193 Sequence Alignment Report, 2009.
John Hopkins Pathology—Ovarian Cancer—http://www.ovariancancer.jhmi.edu/ca125qa.cfm, 2009.
Widschwendter, M., et al., Plosone—3(7)e2656:1-9 (2008).
U.S. Appl. No. 60/298,918, filed Jun. 18, 2001, Dai et al.
Dahia, et al., “Mutation analysis of glial cell line-derived neurotrophic factor (GDNF), a ligand for the RET/GNDF receptor α complex, in sporadic phaeochromocytomas”, Cancer Research, 57:310-313, (1997).
Kotani, et al., “The metastasis suppressor gene kiss-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54”, The journal of Biological Chemistry, vol. 276, No. 37, pp. 34631-34636, (2001).
Harms, et al., “Kiss-1 metastasis suppression and emergent pathways”, Clinical & Experimental Metastasis, 20: 11-18, (2003).
Mason, “The RET receptor tyrosine kinase: activation, signalling and significance in neural development and disease”, Pharmaceutica acta helvetiae, 74:261-264, (2000).
Marsh, et al., “Mutation analysis of glial cell line-derived neurotrophic factor, a ligand for an RET/Coreceptor complex, in multiple endocrine neoplasia type 2 and sporadic neuroendocrine tumors”, JCEM, vol. 82, No. 9, pp. 3025-3028, (1997).
Mulligan, et al., “Investigation of the Genes for RET and its ligand complex, GDNF/GFRα-1, in small cell lung carcinoma”, Genes, Chromosomes & Cancer, 21:326-332, (1998).
Steeg, et al., “Metastasis suppressor genes: basic biology and potential clinical use”, Clinical Breast Cancer, vol. 4, No. 1, pp. 51-62, (2003).
Welch, et al., “Molecular biology of breast cancer metastasis genetic regulation of human breast carcinoma metastasis”, Breast Cancer Research, 2: 408-416, (2000).
Accession No. AK000322; Sugano, et al., Feb. 15, 2000; Database: GBTRANS Search date: Nov. 18, 2003.
Accession No. NM—017763; Kawakami, et al.; Database: GBTRANS Search date: Nov. 18, 2003.
Accession No. Q9NXDO; Kawakami, et al.; Database: GBTRANS Search date: Oct. 1, 2000.
Breenbaum et al., Genome Biology, vol. 4, Issue 9, pp. 117.1-117.8, (2003).
Boon, Adv. Can. Res., 58:117-210, (1992).
Crystal, Science, vol. 270, pp. 404-410, (1995).
Curti, Crit. Rev. Oncology/Hematology, 14:29-39, (1993).
Deonarain, Expert Opin. Ther. Pat., vol. 8, pp. 53-69, (1998).
Ezzell, J. NIH Res., 7:46-49, (1995).
Fu, et al., EMBO Journal, vol. 15, pp. 4392-4401, (1996).
Guo, et al., Journal of Pharmacology and experimental therapeutics, vol. 300, pp. 206-212, (2002).
Gura, et al., Science, 278:1041-1042, (1997).
Hartwell et al., Science, 278:1064-1068, (1997).
Hell, et al., Laboratory Investigation, vol. 73, pp. 492-496, (1995).
Jain, Sci. Am., 271:58-65, (1994).
Miller, FASEB J., vol. 9, pp. 190-199, (1995).
Sambrook, et al., Molecular Cloning, A laboratory Manual, 2ndEdition, Cold springs Harbor, pp. 16.3-16.4, 1989.
Spitler, Cancer Biotherapy, 10:1-3, (1995).
Tokota, et al., Oncogene, vol. 3, pp. 471-475, (1988).
Verma, et al, Nature, vol. 389, pp. 239-242, (1997).
White, et al., Ann. Rev. Med., 52: 125-145, (1991).
Zimmer, Cell motility and the cytoskeleton, vol. 20, pp. 325-337, (1991).
Alladi, et al., “Expression of GDNF receptors GFRalphal and RET is preserved in substantia nigra pars compacta of aging Asian Indians”, Accession No. NM—005264, 2010.
Angrist, et al., “Human GFRA1: Cloning, mapping, genomic sturcture, and evaluation as a candidate gene for hirschsprung disease susceptibility”, Genomics, 48: 354-362, (1998).
Communication from EP 09002988.5 including EBI accession No. Uniprot:P56159; Database accession No. P56159, 2010.
EBI accession No. Uniprot:P56159; Database accession No. P56159; As submitted in EP 09002988.5 communication, 2010.
Hillman, et al., “An unappreciated role for RNA surveillance”, Genome Biology, 5: R8-R16, (2004).
Hishiki, et al., “GDNF-induced differentiation and its enhancement by retinoic acid in primary human neuroblastomas expressing c-Ret and GDNFR-alpha”, GenBank: U95847.1, 1997.
Jing, et al., “GDNF-Induced activation of the Ret protein tyrosine kinase is mediated by GDNFR-α, a novel receptor for GDNF”, Cell, vol. 85, pp. 1113-1124, (1996).
Ota, et al., “Complete sequencing and c
Frantz Gretchen
Hillan Kenneth J.
Phillips Heidi
Polakis Paul
Spencer Susan D.
Aeder Sean E
Arnold & Porter LLP
Fox James A.
Genentech Inc.
Kresnak Mark T.
LandOfFree
Compositions and methods for the diagnosis and treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the diagnosis and treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the diagnosis and treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2619615